Last reviewed · How we verify
Placebo + OBR — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo + OBR (Placebo + OBR) — Otsuka Pharmaceutical Development & Commercialization, Inc.. This is a placebo control arm combined with OBR (a comparator treatment), used in a Phase 3 clinical trial to establish efficacy and safety baselines.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo + OBR TARGET | Placebo + OBR | Otsuka Pharmaceutical Development & Commercialization, Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo + OBR CI watch — RSS
- Placebo + OBR CI watch — Atom
- Placebo + OBR CI watch — JSON
- Placebo + OBR alone — RSS
Cite this brief
Drug Landscape (2026). Placebo + OBR — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-obr. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing